Skip to content
★ Sign in to follow
DE

Donald E. Kuhla

Albany Molecular Research IncSynthetech IncNPS Pharmaceuticals Inc
Total declarations
15
Companies
3
▲ Purchases (7 ops.)
€15k
▼ Sales (0 ops.)
—

Latest filing published 09 Feb 2012 for NPS PHARMACEUTICALS INC.

Insider track record

Disclosed buys
7
Disclosed sells
0
Signal history

No signal scores available.

Closed purchases

Market purchases
7

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Donald E. Kuhla: trading record in brief

Filings by Donald E. Kuhla span 3 companies, the busiest being Synthetech Inc, Albany Molecular Research Inc and NPS Pharmaceuticals Inc. The record holds 15 filings, for trades running from 1 June 2006 to 7 February 2012.

The open-market record is one-sided, with 7 purchases worth €15k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 5 share grants and 3 option exercises.

The median purchase comes to €1,202.

Most recently, on 9 February 2012, the filings show a share grant in NPS Pharmaceuticals Inc. The clock since the last published purchase (12 September 2007) now reads 6,998 days. Typically, a trade is published a median of 1 day after it takes place. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Donald E. Kuhla

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations12 total
  • ◆
    DirectorExecutivesNPS Pharmaceuticals Inc
    0SEC
    15,225 shares0Common StockSEC:0001474064-12-000024:0
  • ◇
    DirectorExecutivesSynthetech Inc
    3,330 USD0SEC
    9,000 shares@ US$0.37Common StockSEC:0001013421-10-000001:0
  • ▲
    DirectorExecutivesSynthetech Inc
    6,249 USD0SEC
    7,811 shares@ US$0.80Common StockSEC:0001013421-07-000002:0
    Canonical exit: 10 Dec 2007 (T+90)
  • ▲
    DirectorExecutivesSynthetech Inc
    2,000 USD0SEC
    2,500 shares@ US$0.80Common StockSEC:0001013421-07-000002:1
    Canonical exit: 11 Dec 2007 (T+90)
  • ▲
    DirectorExecutivesSynthetech Inc
    993 USD0SEC
    1,289 shares@ US$0.77Common StockSEC:0001013421-07-000002:2
    Canonical exit: 11 Dec 2007 (T+90)
  • ▲
    DirectorExecutivesSynthetech Inc
    7,500 USD0SEC
    10,000 shares@ US$0.75Common StockSEC:0001225208-07-007673:0
    Canonical exit: 15 Nov 2007 (T+90)
  • ◇
    DirectorExecutivesSynthetech Inc
    3,700 USD0SEC
    10,000 shares@ US$0.37Common StockSEC:0001013421-07-000001:0
  • ◆
    DirectorExecutivesAlbany Molecular Research Inc
    15,005 USD0SEC
    1,037 shares@ US$14.47Common StockSEC:0001179110-07-012308:0
  • ▲
    DirectorExecutivesSynthetech Inc
    992 USD0SEC
    2,480 shares@ US$0.40Common StockSEC:0001225208-06-005790:0
    Canonical exit: 18 Feb 2007 (T+90)
  • ▲
    DirectorExecutivesSynthetech Inc
    1,544 USD0SEC
    3,860 shares@ US$0.40Common StockSEC:0001225208-06-005790:1
    Canonical exit: 19 Feb 2007 (T+90)
  • ▲
    DirectorExecutivesSynthetech Inc
    1,464 USD0SEC
    3,660 shares@ US$0.40Common StockSEC:0001013421-06-000002:0
    Canonical exit: 14 Feb 2007 (T+90)
  • ◆
    Executive Vice PresidentExecutivesAlbany Molecular Research Inc
    9,997 USD0SEC
    964 shares@ US$10.37Common StockSEC:0001179110-06-012546:0

12 of 12 declarations